Previous 10 | Next 10 |
home / stock / azn / azn articles
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023. ...
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody prog...
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct compreh...
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-t...
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy o...
The White House is endorsing a contentious power that permits the government to reclaim patents for specific high-cost medications.&...
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDA...
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, includ...
AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-CKD and DIALIZE-Outcomes Phase 3 evidence trials for Lokelma (sod...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...